PengL retweetledi

Real‑world, 8‑year multicancer study of lenvatinib shows manageable long‑term use across DTC, AdCC, HCC & EC. Notably, BMI declined during treatment (p=0.045), highlighting the need for closer monitoring in low‑BMI patients.
🔗 buff.ly/Ckygpuz
#Lenvatinib @elenacolomboMD

English




















